MDWD Strangle Strategy
MDWD (MediWound Ltd.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MDWD (MediWound Ltd.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $176.5M, a beta of 0.22 versus the broader market, a 52-week range of 14.9-22.505, average daily share volume of 86K, a public-listing history dating back to 2014, approximately 111 full-time employees. These structural characteristics shape how MDWD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.22 indicates MDWD has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on MDWD?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current MDWD snapshot
As of May 15, 2026, spot at $16.57, ATM IV 51.30%, IV rank 5.44%, expected move 14.71%. The strangle on MDWD below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 126-day expiry.
Why this strangle structure on MDWD specifically: MDWD IV at 51.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a MDWD strangle, with a market-implied 1-standard-deviation move of approximately 14.71% (roughly $2.44 on the underlying). The 126-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MDWD expiries trade a higher absolute premium for lower per-day decay. Position sizing on MDWD should anchor to the underlying notional of $16.57 per share and to the trader's directional view on MDWD stock.
MDWD strangle setup
The MDWD strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MDWD near $16.57, the first option leg uses a $17.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MDWD chain at a 126-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MDWD shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $17.00 | $1.70 |
| Buy 1 | Put | $16.00 | $1.93 |
MDWD strangle risk and reward
- Net Premium / Debit
- -$362.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$362.50
- Breakeven(s)
- $12.38, $20.63
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
MDWD strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on MDWD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | +$1,236.50 |
| $3.67 | -77.8% | +$870.24 |
| $7.34 | -55.7% | +$503.98 |
| $11.00 | -33.6% | +$137.72 |
| $14.66 | -11.5% | -$228.55 |
| $18.32 | +10.6% | -$230.19 |
| $21.99 | +32.7% | +$136.07 |
| $25.65 | +54.8% | +$502.33 |
| $29.31 | +76.9% | +$868.59 |
| $32.97 | +99.0% | +$1,234.85 |
When traders use strangle on MDWD
Strangles on MDWD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MDWD chain.
MDWD thesis for this strangle
The market-implied 1-standard-deviation range for MDWD extends from approximately $14.13 on the downside to $19.01 on the upside. A MDWD long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current MDWD IV rank near 5.44% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on MDWD at 51.30%. As a Healthcare name, MDWD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MDWD-specific events.
MDWD strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MDWD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MDWD alongside the broader basket even when MDWD-specific fundamentals are unchanged. Always rebuild the position from current MDWD chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on MDWD?
- A strangle on MDWD is the strangle strategy applied to MDWD (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With MDWD stock trading near $16.57, the strikes shown on this page are snapped to the nearest listed MDWD chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are MDWD strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MDWD strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 51.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$362.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a MDWD strangle?
- The breakeven for the MDWD strangle priced on this page is roughly $12.38 and $20.63 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MDWD market-implied 1-standard-deviation expected move is approximately 14.71%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on MDWD?
- Strangles on MDWD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MDWD chain.
- How does current MDWD implied volatility affect this strangle?
- MDWD ATM IV is at 51.30% with IV rank near 5.44%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.